Labcorp Holdings Inc. LH
370.88 USD -0.95 (-0.26%)
At closeNov 10, 2026, 5:05 PM EST
370.88 0.00 0.00%
After hours · Nov 10, 5:05 PM ET
363.19 Day range 372.69
245.00 52-week range 373.76
- YTD
- +47.83%
- 1 year
- +42.03%
News
zacks.com Is Now the Right Time to Hold Labcorp Stock in Your Portfolio? LH's specialty testing growth, AI-driven efficiencies and expanding margins support its outlook, though currency pressures and competition pose risks.
defenseworld.net Labcorp (NYSE:LH) Hits New 52-Week High on Analyst Upgrade Labcorp Holdings Inc. (NYSE: LH - Get Free Report)'s stock price reached a new 52-week high on Thursday after HSBC upgraded the stock from a hold rating to a buy rating. HSBC now has a $410.00 price…
zacks.com Labcorp Holdings (LH) is a Top-Ranked Momentum Stock: Should You Buy? Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
247wallst.com Buy, Sell, or Hold? Thursday’s Top Upgrades and Downgrades: Block, Cisco Systems, Dollar Tree, First Solar, HubSpot, JetBlue Airways, Nike, Space-X, Skyworks Solutions, and More Stocks surged after a political shake-up, but Wall Street analysts were far from unanimous on Thursday. Some household names got slashed while a struggling airline and a solar giant won new fans.…
prnewswire.com Labcorp to Speak at the UBS Global Healthcare Conference BURLINGTON, N.C., Nov. 4, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that Chief Financial Officer Julia Wang will…
benzinga.com UBS Maintains Buy on Labcorp Holdings, Raises Price Target to $420 UBS analyst Kevin Caliendo maintains Labcorp Holdings (NYSE:LH) with a Buy and raises the price target from $380 to $420.
benzinga.com Barclays Maintains Equal-Weight on Labcorp Holdings, Raises Price Target to $380 Barclays analyst Luke Sergott maintains Labcorp Holdings (NYSE:LH) with a Equal-Weight and raises the price target from $330 to $380.
benzinga.com Truist Securities Maintains Buy on Labcorp Holdings, Raises Price Target to $395 Truist Securities analyst David Macdonald maintains Labcorp Holdings (NYSE:LH) with a Buy and raises the price target from $365 to $395.- benzinga.com Baird Maintains Outperform on Labcorp Holdings, Raises Price Target to $396 Baird analyst Eric Coldwell maintains Labcorp Holdings (NYSE:LH) with a Outperform and raises the price target from $361 to $396.
benzinga.com Labcorp Targets Margin Growth, Absorbs Policy Headwinds Labcorp shares reach a 52-week high after beating Q3 consensus estimates. The company raises fiscal 2026 guidance and expands diagnostic acquisitions.
benzinga.com SK Hynix, Vertiv Rescue AI Trade As Oil Tops $102 Before Fed: Stock Market Today Stock market today: SK hynix and Vertiv rally on AI-driven results as oil tops $102 on Iran fears and the 10-year yield tops 5% before the Fed; SMH gains.
benzinga.com Vertiv, Evercore, Brinker, GE HealthCare And Other Big Stocks Moving Higher On Wednesday U.S. stocks mixed; Dow gained ~100 points. Vertiv jumped 13.3% on strong results and raised guidance; Ultralife soared 145.8% on buyout news.
benzinga.com Labcorp Hldgs Q3 2026 Earnings Call Transcript Labcorp Hldgs (NYSE:LH) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you…- benzinga.com Labcorp Holdings Raises FY2026 Adj EPS Guidance from $18.10-$18.55 to $18.30-$18.70 vs $18.36 Est; Raises FY2026 Sales Guidance from $14.710B-$14.827B to $14.779B-$14.887B vs $14.749B Est Labcorp Holdings (NYSE:LH) raises FY2026 Adj EPS guidance from $18.10-$18.55 to $18.30-$18.70 vs $18.36 analyst estimate. Raises FY2026 sales outlook from $14.710 billion-$14.827 billion to $14.779…
benzinga.com Laboratory Corp Q3 Adj. EPS $4.78 Beats $4.66 Estimate, Sales $3.810B Beat $3.759B Estimate Laboratory Corp (NYSE:LH) reported quarterly earnings of $4.78 per share which beat the analyst consensus estimate of $4.66 by 2.58 percent. This is a 14.35 percent increase over earnings of $4.18…
benzinga.com Waters And Labcorp To Expand Access To BD Onclarity HPV Assay Labcorp intends to be the first commercial laboratory to offer FDA-approved HPV testing with the BD Onclarity™ HPV Assay across clinician-collected and self-collected screening options in clinic,…
benzinga.com Charles River Laboratories Announces Research Collaboration Agreement With FDA And Labcorp For Developing Sensitive Screening Tools To Quantify And Rank Abuse Potential Of New Drugs Joint research effort seeks to improve abuse potential assessment tools to support drug development and public health decision-makingCharles River Laboratories International, Inc. (NYSE:CRL) today…
benzinga.com Myriad Genetics Offloads Struggling Prenatal Unit for $210 Million to Labcorp Labcorp will purchase Myriad Genetics' prenatal testing business for $210 million in cash, projecting $160 million in year-one revenue.- benzinga.com Myriad Genetics To Sell Its Prenatal Health Testing Business, Including Prequel, Foresight, SneakPeek And FirstGene Tests, To Labcorp For $210M In Cash Plus Inventory Value When complete, the transaction is expected to provide more patients and physicians with expanded access to Labcorp’s comprehensive, high-quality laboratory services, convenient patient service center…
benzinga.com OPKO Health Sheds Diagnostics Businesses in Major Labcorp Deal OPKO Health jumps 18% and Labcorp trades higher as LH acquires BioReference Health assets in an $872M deal.- benzinga.com UPDATE: Labcorp Agrees To Acquire Select Assets Of OPKO Health's BioReference Health Subsidiary For $722M In Cash, Up To Additional $150M In Earnout On Revenue Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (NASDAQ:OPK), a multinational biopharmaceutical company, announced today that they have…
benzinga.com Labcorp Agrees To Acquire Select Assets Of OPKO Health's BioReference Health Subsidiary For $722M In Cash, Up To Additional $150M In Earnout On Revenue Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (NASDAQ:OPK), a multinational biopharmaceutical company, announced today that they have…- benzinga.com Labcorp Reaffirms 2026–2029 Long-Term Outlook Following CMS Preliminary Medicare Payment Rate Release; Expects Compound Annual Adj EPS Growth Of 8.5%-11.5% In 2026-2029 On September 21, 2026, the Centers for Medicare & Medicaid Services ("CMS") released preliminary Clinical Laboratory Fee Schedule payment rates applicable from 2027 through 2029 pursuant to the…
benzinga.com Ericsson, Lexeo Therapeutics And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. stock futures were mixed. Ericsson fell 4.3% after a Morgan Stanley downgrade; Quest Diagnostics, Rambus and others also declined premarket.- benzinga.com Truist Securities Maintains Buy on Labcorp Holdings, Raises Price Target to $365 Truist Securities analyst David Macdonald maintains Labcorp Holdings (NYSE:LH) with a Buy and raises the price target from $350 to $365.
benzinga.com Deal Dispatch: Bending Spoons Acquires Miro For $1.35B, Kinetik Up For Sale, LIV Golf Bankruptcy Read this week's top deal updates, including Bending Spoons' Miro deal, Chime's Stride Bank purchase, and the LIV Golf bankruptcy.
benzinga.com UBS Maintains Buy on Labcorp Holdings, Raises Price Target to $380 UBS analyst Kevin Caliendo maintains Labcorp Holdings (NYSE:LH) with a Buy and raises the price target from $361 to $380.- benzinga.com Barclays Maintains Equal-Weight on Labcorp Holdings, Raises Price Target to $330 Barclays analyst Luke Sergott maintains Labcorp Holdings (NYSE:LH) with a Equal-Weight and raises the price target from $320 to $330.
benzinga.com Labcorp Bets Big on AI, Specialty Testing to Drive Growth Through 2029 Labcorp shares its strategic priorities and reaffirms 2026 guidance at its Investor Day, forecasting steady revenue growth through 2029.- benzinga.com Labcorp Provides Long-Term Outlook Through 2029, With 5%-8% Revenue CAGR And 8.5%-11.5% Adj EPS CAGR Reaffirms full-year 2026 guidanceProvides long-term outlook through 2029, with compound annual revenue growth of 5% to 8% and compound annual adjusted earnings per share (EPS) growth of 8.5% to…
- benzinga.com Labcorp Holdings Affirms FY2026 Adj EPS Guidance of $18.10-$18.55 vs $18.01 Est; Affirms FY2026 Sales Guidance of $14.710B-$14.827B vs $14.707B Est Labcorp Holdings (NYSE:LH) affirms FY2026 Adj EPS guidance from $18.10-$18.55 to $18.10-$18.55 vs $18.01 analyst estimate. Affirms FY2026 sales outlook from $14.710 billion-$14.827 billion to $14.710…
- benzinga.com Labcorp Acquires MLM Medical Labs; Financial Terms Not Disclosed Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the acquisition of MLM Medical Labs (MLM), a leading global central and specialty laboratory…
- benzinga.com Labcorp To Offer Elecsys pTau-217 Test Following Clearance By FDA Elecsys® pTau-217 is the first and only FDA-cleared single-biomarker blood test to both rule in and rule out amyloid pathology across specialty and primary care settingsMeasures phosphorylated Tau…
- benzinga.com Labcorp And NACHC Announce Strategic Alliance To Support Practice Improvement And Advance Community Health Initiatives Across Community Health Center Network Collaboration will support leadership development, practice improvement and innovation across the nation's Community Health CentersBURLINGTON, N.C. and BETHESDA, Md., Aug. 18, 2026 /PRNewswire/ --…
- benzinga.com Labcorp Announces Availability of Roche's Ventana Pten RxDx Assay, First Immunohistochemistry Companion Diagnostic Test Approved By FDA To Determine Pten Protein Loss In Prostate Adenocarcinoma Patients The assay helps identify patients who may be eligible for treatment with AstraZeneca's TRUQAP® (capivasertib) in combination with abiraterone acetate and prednisone.
- benzinga.com JP Morgan Maintains Overweight on Labcorp Holdings, Raises Price Target to $360 JP Morgan analyst Lisa Gill maintains Labcorp Holdings (NYSE:LH) with a Overweight and raises the price target from $330 to $360.
- benzinga.com Morgan Stanley Maintains Overweight on Labcorp Holdings, Raises Price Target to $338 Morgan Stanley analyst Ricky Goldwasser maintains Labcorp Holdings (NYSE:LH) with a Overweight and raises the price target from $308 to $338.
benzinga.com Truist Securities Maintains Buy on Labcorp Holdings, Raises Price Target to $350 Truist Securities analyst David Macdonald maintains Labcorp Holdings (NYSE:LH) with a Buy and raises the price target from $320 to $350.- benzinga.com Barclays Maintains Equal-Weight on Labcorp Holdings, Raises Price Target to $320 Barclays analyst Jack Meehan maintains Labcorp Holdings (NYSE:LH) with a Equal-Weight and raises the price target from $290 to $320.
- benzinga.com Labcorp Holdings Raises FY2026 Adj EPS Guidance from $17.70-$18.35 to $18.10-$18.55 vs $18.01 Est; Raises FY2026 Sales Guidance from $14.650B-$14.800B to $14.710B-$14.827B vs $14.707B Est Labcorp Holdings (NYSE:LH) raises FY2026 Adj EPS guidance from $17.70-$18.35 to $18.10-$18.55 vs $18.01 analyst estimate. Raises FY2026 sales outlook from $14.650 billion-$14.800 billion to $14.710…
- benzinga.com Laboratory Corp Q2 Adj. EPS $4.99 Beats $4.78 Estimate, Sales $3.731B Beat $3.711B Estimate Laboratory Corp (NYSE:LH) reported quarterly earnings of $4.99 per share which beat the analyst consensus estimate of $4.78 by 4.39 percent. This is a 14.71 percent increase over earnings of $4.35…
- benzinga.com B of A Securities Maintains Buy on Labcorp Holdings, Raises Price Target to $320 B of A Securities analyst Michael Ryskin maintains Labcorp Holdings (NYSE:LH) with a Buy and raises the price target from $300 to $320.
- benzinga.com Baird Maintains Outperform on Labcorp Holdings, Raises Price Target to $338 Baird analyst Eric Coldwell maintains Labcorp Holdings (NYSE:LH) with a Outperform and raises the price target from $335 to $338.
- benzinga.com Labcorp Announces Nationwide Availability Of ColoSense, Its RNA-Based, At-Home Colorectal Cancer Screening Test First FDA-approved, at-home screening test that uses RNA technology to detect biomarkers associated with colorectal cancer and advanced adenomasDesigned to reduce common barriers to at-home screening…
- benzinga.com Labcorp Enters Collaboration The Alliance For Clinical Trials In Oncology To Advance A National, Multicenter Clinical Trial For Patients Newly Diagnosed With Colorectal Cancer The trial will evaluate approaches to increase germline genetic testing among at-risk family members, as well as the impact of multigene panel testing on care for newly diagnosed patients. Leveraging…
- benzinga.com Labcorp Announces Availability Of Expanded DPYD Genotyping Test To Help Identify Cancer Patients At Increased Risk For Severe Fluoropyrimidine Chemotherapy Side Effects New pharmacogenomic test detects all DPYD variants recommended by the Association for Molecular Pathology to support safer, more personalized cancer treatmentBURLINGTON, N.C., May 28, 2026…
- benzinga.com Labcorp Launches MyLabcorp AI App, Integrating Lab Results And Guideline‑Based Health Content MyLabcorp connects lab results, educational content and AI-enabled features in a secure, personalized mobile experienceLeverages OpenAI models designed to help users understand their results, ask…
- benzinga.com Labcorp Expands Collaboration With Epic; Labcorp's Full Test Menu To Be Available Through Aura, Epic's Unified Platform For Ordering And Receiving Lab Results Labcorp's full test menu will be available through Epic's Aura platformIntegration builds on the successful deployment of Invitae genetic testing and accelerates access to the latest genetic and…
benzinga.com Labcorp Advances As AI Investments, Core Businesses Drive Growth Labcorp shares rise after Q1 earnings beat and higher guidance, supported by diagnostics growth and investments in AI and robotics.
benzinga.com Earnings Scheduled For April 30, 2026